Objective： To study the effects of tetramethylpyrazine （TMP） on cardiac function and mortality rate in septic rats. Methods： Fifty male Sprague-Dawley rats were randomized into a sham-operation group （sham group,...Objective： To study the effects of tetramethylpyrazine （TMP） on cardiac function and mortality rate in septic rats. Methods： Fifty male Sprague-Dawley rats were randomized into a sham-operation group （sham group, n=10）, normal saline group （NS group, n=20）, and TMP group （n=20）. The rats in the NS and TMP groups underwent cecal ligation and puncture （CLP） to induce sepsis. Rats in the NS group were injected with NS （10 mL/kg） immediately after CLP and 6 h after CLP. Rats in the TMP group were injected with TMP （10 mg/kg） at the same time points. Twenty-four hours after modeling, the mortality rates were observed in each group. Cardiac function and serum concentration of tumor necrosis factor α （TNF-α） were also tested. The correlation between TNF-α and the ejection fraction （EF） was observed. Left ventricle specimens were reserved for histomorphologic study. Results： Compared with the sham group, the NS and TMP groups had decreased EF values and increased mortality rates and serum TNF-α levels （P〈0.05）. The TMP group had a comparatively lower mortality rate and TNF-α level and a higher EF value compared with the NS group （P〈0.05）. Histomorphology indicated that myocardial inflammation in the TMP group was mild compared with that in the NS group. There was a negative correlation between TNF-α level and EF value （r=-0.583, P=0.000）. Conclusion： TMP could reduce the mortality rate of septic rats and had certain protective effects on cardiac function.展开更多
目的探讨强化心率控制指导药物治疗慢性心力衰竭的疗效及其安全性。方法确诊慢性心力衰竭患者156例,纽约心脏病协会(New York Heark Association,NYHA)分级为II^IV级,所有患者经最佳的药物治疗稳定后,按数字表法随机分为治疗组(78例)和...目的探讨强化心率控制指导药物治疗慢性心力衰竭的疗效及其安全性。方法确诊慢性心力衰竭患者156例,纽约心脏病协会(New York Heark Association,NYHA)分级为II^IV级,所有患者经最佳的药物治疗稳定后,按数字表法随机分为治疗组(78例)和对照组即常规治疗组(78例)。治疗组在常规治疗基础上,以患者清晨静息心率降至55~60次/min为目标心率指导药物治疗。控制心率采用的药物为酒石酸美托洛尔或琥珀酸美托洛尔,酒石酸美托洛尔起始剂量为6.25 mg,2次/d,或琥珀酸美托洛尔起始剂量为11.875 mg/d,根据病情逐渐增至目标剂量或最大耐受剂量。比较两组治疗前及治疗12个月后的NYHA分级、左心室心肌质量、左心室射血分数和左心室后壁收缩期增厚率(△T%)的变化,以及两组全因病死率和心力衰竭恶化住院率。结果治疗12个月后,治疗组患者的临床症状改善情况明显优于对照组(总体有效率:94.8%vs.73.1%,P<0.01);同时,治疗组左心室心肌质量的减少幅度,左心室射血分数和左心室后壁收缩期增厚率的升高幅度均明显高于对照组,且差异有统计学意义(9.39%vs.3.59%,P<0.05;18.34%vs.11.62%,P<0.01;20.43%vs.10.64%,P<0.05);两组均未发生死亡患者,而治疗组因心力衰竭恶化住院治疗的次数明显少于对照组,差异有统计学意义(13次vs.32次,P<0.01)。结论强化心率控制指导药物治疗慢性心力衰竭安全有效,可改善患者临床症状、提高心功能、改善心肌重构,减少因心力衰竭恶化住院治疗次数。展开更多
基金Supported by the Fund for Social Development Project from Department of Science and Technology,Guangdong Province, China(No.2011KT1988)
文摘Objective： To study the effects of tetramethylpyrazine （TMP） on cardiac function and mortality rate in septic rats. Methods： Fifty male Sprague-Dawley rats were randomized into a sham-operation group （sham group, n=10）, normal saline group （NS group, n=20）, and TMP group （n=20）. The rats in the NS and TMP groups underwent cecal ligation and puncture （CLP） to induce sepsis. Rats in the NS group were injected with NS （10 mL/kg） immediately after CLP and 6 h after CLP. Rats in the TMP group were injected with TMP （10 mg/kg） at the same time points. Twenty-four hours after modeling, the mortality rates were observed in each group. Cardiac function and serum concentration of tumor necrosis factor α （TNF-α） were also tested. The correlation between TNF-α and the ejection fraction （EF） was observed. Left ventricle specimens were reserved for histomorphologic study. Results： Compared with the sham group, the NS and TMP groups had decreased EF values and increased mortality rates and serum TNF-α levels （P〈0.05）. The TMP group had a comparatively lower mortality rate and TNF-α level and a higher EF value compared with the NS group （P〈0.05）. Histomorphology indicated that myocardial inflammation in the TMP group was mild compared with that in the NS group. There was a negative correlation between TNF-α level and EF value （r=-0.583, P=0.000）. Conclusion： TMP could reduce the mortality rate of septic rats and had certain protective effects on cardiac function.
